Inhibrx Biosciences reported earnings of -$ 2.46 per INBX share on Nov 13, 2026, beating analysts' expectations by
| Report Date | Nov 13, 2026 |
|---|---|
| Forecasted EPS | -$ 2.45 |
| Earnings Per Share (Surprise) | -$ 2.46 (-$ 0.01) |
| Last Year's EPS | -$ 2.26 |
| EPS YoY Change |
Out of the last 35 earnings reporting periods, Inhibrx Biosciences beat analysts’ expectations 8 times and fell short of expectations 17 time(s). Inhibrx Biosciences reported earnings per share of -$ 2.46 in the last report falling to reach an estimated EPS of -$ 2.45 by
| Report Date | Forecasted EPS | Reported EPS | Last Year's EPS | EPS YoY Change |
|---|---|---|---|---|
| Nov 13, 2026 | -$ 2.45 | -$ 2.46 | -$ 2.28 | |
| Aug 13, 2026 | -$ 2.28 | -$ 2.34 | -$ 1.85 | |
| May 14, 2026 | -$ 2.37 | -$ 2.15 | -$ 2.80 | |
| Mar 19, 2026 | -$ 2.08 | -$ 2.11 | -$ 3.09 | |
| Nov 14, 2025 | -$ 2.08 | -$ 2.28 | -$ 2.84 | |
| Aug 13, 2025 | -$ 2.92 | -$ 1.85 | $ 125.48 | |
| May 14, 2025 | -$ 2.55 | -$ 2.80 | -$ 1.44 | |
| Mar 17, 2025 | -$ 2.88 | -$ 3.09 | -$ 1.73 | |
| Nov 14, 2024 | -$ 3.06 | -$ 2.84 | -$ 1.10 | |
| Aug 13, 2024 | -$ 3.60 | $ 125.48 | -$ 1.08 | |
| Jun 3, 2024 | -$ 1.04 | -$ 1.44 | -$ 1.12 | |
| Feb 28, 2024 | -$ 1.07 | -$ 1.73 | -$ 0.95 | |
| Nov 9, 2023 | -$ 1.01 | -$ 1.10 | -$ 0.90 | |
| Aug 7, 2023 | -$ 1.02 | -$ 1.08 | -$ 0.97 | |
| May 8, 2023 | -$ 0.84 | -$ 1.12 | -$ 0.80 | |
| Mar 6, 2023 | -$ 0.80 | -$ 0.95 | -$ 0.55 | |
| Nov 7, 2022 | -$ 1.01 | -$ 0.90 | -$ 0.54 | |
| Aug 8, 2022 | -$ 0.84 | -$ 0.97 | -$ 0.55 | |
| May 9, 2022 | -$ 0.62 | -$ 0.80 | -$ 0.51 | |
| Feb 28, 2022 | -$ 0.53 | -$ 0.55 | -$ 0.47 |
Inhibrx Biosciences’s stock was trading at $ 87.75 on Nov 12, 2026 a day before the last earnings report was released.
| Report Date | EPS | Price 1 Day Before | Price 1 Day After | Change |
|---|---|---|---|---|
| Nov 13, 2026 | -$ 2.46 | $ 87.75 | ||
| Aug 13, 2026 | -$ 2.34 | $ 98.36 | $ 88.37 | |
| May 14, 2026 | -$ 2.15 | $ 117.95 | $ 108.64 | |
| Mar 19, 2026 | -$ 2.11 | $ 68.69 | $ 60.92 | |
| Nov 14, 2025 | -$ 2.28 | $ 74.62 | $ 77.35 | |
| Aug 13, 2025 | -$ 1.85 | $ 21.92 | $ 23.94 | |
| May 14, 2025 | -$ 2.80 | $ 11.28 | $ 12.02 | |
| Mar 17, 2025 | -$ 3.09 | $ 14.10 | $ 14.00 | |
| Nov 14, 2024 | -$ 2.84 | $ 15.45 | $ 13.83 | |
| Aug 13, 2024 | $ 125.48 | $ 11.25 | $ 11.29 | |
| Jun 3, 2024 | -$ 1.44 | $ 17.21 |
Inhibrx Biosciences released its most recent earnings reports in November 2026, August 2026, May 2026, March 2026 respectively. Generally, most companies have a consistent schedule for their earnings releases. However, companies do not necessarily release their earnings reports at the same time each year. The timing of earnings releases can vary depending on a company's fiscal year, industry norms, and internal reporting practices.
Inhibrx Biosciences missed analysts’ expectations during the last earnings period by
